Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Medicine"
DOI: 10.1007/s10238-022-00830-3
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening acquired blood disease characterized by chronic complement-mediated hemolysis and thrombosis. On May 14, 2021, the US FDA approved a new targeted C3 therapy Empaveli (pegcetacoplan), once called… read more here.
Keywords: paroxysmal nocturnal; nocturnal hemoglobinuria; novel targeted; pegcetacoplan ... See more keywords
Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Sign Up to like & getrecommendations! Published in 2021 at "Current medical research and opinion"
DOI: 10.1080/03007995.2021.1971182
Abstract: OBJECTIVE In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously treated… read more here.
Keywords: treated eculizumab; ravulizumab; pegcetacoplan; comparative effectiveness ... See more keywords
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221114673
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction. Until recently, C5 inhibition with eculizumab or ravulizumab represented the only therapies approved… read more here.
Keywords: safety; nocturnal hemoglobinuria; pegcetacoplan; paroxysmal nocturnal ... See more keywords